Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORACLE: Osimertinib Rechallenge With or Without Chemotherapy After ADAURA
jRCTs051260032Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival (PFS). Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051260032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260032.